![Adobe_668054529 UCB EHSF 2024](/cdn-cgi/image/format=auto/globalassets/learning-zones-and-sponsored-congress/ucb---ehsf-congress-highlights/ucb-ehsf-2024_hero.webp?preset=df)
Advances in hidradenitis suppurativa
Transcript: Comorbidities and patient-provider viewpoints
Dr Philippe Guillem
Interview recorded Feb 2024, EHSF 2024. All transcripts are created from interview footage and directly reflect the content of the interview at the time. The content is that of the speaker and is not adjusted by Medthority.
The comorbidities session was really interesting, because it highlighted the fact that HS is really a systemic disease associated with several comorbidities. We had, for example, communication that suggested dulling the disease has an important comorbidity and it's a follicular comorbidity that could also influence the prognosis of HS. This study was from Spain. We also had studies from Spain, from Ireland, from US highlighting the well-known inflammatory comorbidities such as IBDs. And the question raised by the study is whether we can use systematic screening for IBD in HS patients for example, using calprotectin. It's probably what we are going to. Another important inflammatory comorbidity reported by US team was about non-infectious varieties that extends the field of inflammatory comorbidities.
Another very important point in HS patients in the fact that many comorbidities are on the field of cardiovascular disease and metabolic disease. We have a study from US about the association to the NASH liver fibrosis. We also had communication about the increased risk of major cardiovascular event. And it's really something important in the clinical practice to detect and screen for this cardiovascular comorbidities in HS. The interactive session was dedicated to have in the main room, the preliminary session both patients and healthcare providers. And we asked the audience to answer live to several question related to HS clinical case. And we expected, and it is what we observed different answers depending on the quality of those who answered, whether they're patients or HCPs. And the aim of the study was to demonstrate to practitioners that their answer were sometimes not received as pertinent, relevant for the patients. And we also achieve to show to the patients how the physicians are thinking when they ask some question that seem inappropriate. The main aim of this interactive session was to show patients and the physicians that they have different points of view, but they belongs to the same therapeutic team. So that was really important for this interactive session.
Updates in your area
of interest
of interest
Articles your peers
are looking at
are looking at
Bookmarks
saved
saved
Days to your
next event
next event
This content has been developed independently of the sponsor, UCB Biopharma SRL, which has had no editorial input into the content. EPG Health received funding from the sponsor in order to help provide its healthcare professional members with access to the highest quality medical and scientific information, education and associated relevant content. This content is intended for healthcare professionals only.